Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.70 |
| ▸ | RXRA | P19793 | 13/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245808 | 0.82 | NOTUM (1.00) | NOTUMRXRAGRIN1GRIN2BKCNH2 | |
| Hydrochloric Acid SCHEMBL23451812 | 0.81 | NOTUM (0.97) | NOTUMRXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL18965360 | 0.78 | NOTUM (0.62) | NOTUM | |
| SCHEMBL19219401 | 0.78 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19219405 | 0.77 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL10447579 | 0.76 | NOTUM (0.54) | NOTUMKCNH2 | |
| SCHEMBL17502204 | 0.76 | KCNH2 (1.00) | NOTUMRXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219399 | 0.75 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211422 | 0.75 | NOTUM (0.80) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL19219400 | 0.74 | RXRA (1.00) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | TOP2A, TOP2B, TOP1 | NOTUM 3217/4885RXRA 2513/4885GRIN1 4270/4885 |
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | TOP2A, TOP2B, TOP1 | NOTUM 3217/4885RXRA 2513/4885GRIN1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.